Search Results - Christof Vulsteke

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report by Danielle Delombaerde, Delphine Vervloet, Dieter Berwouts, Roel Beckers, Hans Prenen, Marc Peeters, Félix Gremonprez, Lieselot Croes, Christof Vulsteke

    Published in Journal of Medical Case Reports (2022-07-01)
    Get full text
    Article


  2. 2

    First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients by Christof Vulsteke, Laurens De Cocker, Alfonso Gómez de Liaño, Cristina Montesdeoca, Astrid De Meulenaere, Lieselot Croes, Danielle Delombaerde, Bernadett Szabados, Thomas Powles

    Published in Pharmaceuticals (2023-03-01)
    Get full text
    Article


  3. 3

    Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study by Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico Van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke

    Published in Pharmaceuticals (2023-04-01)
    Get full text
    Article


  4. 4

    <i>POLRMT</i> as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients by Alejandro Velasco-Ruiz, Rocio Nuñez-Torres, Guillermo Pita, Hans Wildiers, Diether Lambrechts, Sigrid Hatse, Danielle Delombaerde, Thomas Van Brussel, M. Rosario Alonso, Nuria Alvarez, Belen Herraez, Christof Vulsteke, Pilar Zamora, Teresa Lopez-Fernandez, Anna Gonzalez-Neira

    Published in Pharmaceutics (2021-11-01)
    Get full text
    Article


  5. 5

    Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors by Danielle Delombaerde, Christof Vulsteke, Nico Van de Veire, Delphine Vervloet, Veronique Moerman, Lynn Van Calster, Anne-Marie Willems, Lieselot Croes, Félix Gremonprez, Astrid De Meulenaere, Ximena Elzo Kraemer, Kristien Wouters, Marc Peeters, Hans Prenen, Johan De Sutter

    Published in Pharmaceuticals (2024-07-01)
    Get full text
    Article


  6. 6

    Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? by Alexander Decruyenaere, Gennigens Christine, Rottey Sylvie, Laenen Annouschka, Emmanuel Seront, Els Everaert, Philip R Debruyne, Heidi Van Den Bulck, Julie Bastin, Verbiest Annelies, Christof Vulsteke, Peter Schatteman, Daisy Luyten, Sandrine Aspeslagh, Nieves Martinez-Chanza, Marlies De Bock, Thomas Meyskens, Jolanda Verheezen, Barbara Brouwers, Benoit Beuselinck

    Published in Acta Oncologica (2025-07-01)
    Get full text
    Article


  7. 7

    Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients by Yana Debie, Irene Garcia-Fogeda, Lander Willem, Ella Roelant, Lise Verbruggen, Greetje Vanhoutte, Lieselot Croes, Christof Vulsteke, Wim Demey, Willem Lybaert, Marianne Hanssens, Alain Bols, Johan Van ongeval, Ann De Becker, Hilde Jansens, Maria E. Goossens, Annelies Janssens, Hans Prenen, Sébastien Anguille, Marc Peeters, Peter A. van Dam, Niel Hens, Steven Abrams, Timon Vandamme

    Published in Scientific Reports (2025-03-01)
    Get full text
    Article


  8. 8

    Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study by Chantal F. Stockem, Sarah M. H. Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Dimitra R. Bakaloudi, Rafee Talukder, Belen Caramelo, Rafael Morales-Barrera, Astrid De Meulenaere, Alessandro Rametta, Andrea Bottelli, Felix Lefort, Patrizia Giannatempo, Christof Vulsteke, Joan Carles, Ignacio Duran, Petros Grivas, Alfonso Gómez de Liaño, Debbie G. J. Robbrecht, Begoña P. Valderrama, Vincent van der Noort, Michiel S. van der Heijden

    Published in BJC Reports (2024-10-01)
    Get full text
    Article


  9. 9

    Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk by Aurora Gómez-Vecino, Roberto Corchado-Cobos, Adrián Blanco-Gómez, Natalia García-Sancha, Sonia Castillo-Lluva, Ana Martín-García, Marina Mendiburu-Eliçabe, Carlos Prieto, Sara Ruiz-Pinto, Guillermo Pita, Alejandro Velasco-Ruiz, Carmen Patino-Alonso, Purificación Galindo-Villardón, María Linarejos Vera-Pedrosa, José Jalife, Jian-Hua Mao, Guillermo Macías de Plasencia, Andrés Castellanos-Martín, María del Mar Sáez-Freire, Susana Fraile-Martín, Telmo Rodrigues-Teixeira, Carmen García-Macías, Julie Milena Galvis-Jiménez, Asunción García-Sánchez, María Isidoro-García, Manuel Fuentes, María Begoña García-Cenador, Francisco Javier García-Criado, Juan Luis García-Hernández, María Ángeles Hernández-García, Juan Jesús Cruz-Hernández, César Augusto Rodríguez-Sánchez, Alejandro Martín García-Sancho, Estefanía Pérez-López, Antonio Pérez-Martínez, Federico Gutiérrez-Larraya, Antonio J. Cartón, José Ángel García-Sáenz, Ana Patiño-García, Miguel Martín, Teresa Alonso-Gordoa, Christof Vulsteke, Lieselot Croes, Sigrid Hatse, Thomas Van Brussel, Diether Lambrechts, Hans Wildiers, Hang Chang, Marina Holgado-Madruga, Anna González-Neira, Pedro L. Sánchez, Jesús Pérez Losada

    Published in Cells (2023-07-01)
    Get full text
    Article


Search Tools: